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a  b  s  t  r  a  c  t
Mastocytosis  are  myeloproliferative  neoplasms  commonly  related  to gain-of-function  mutations  involv-
ing the  tyrosine  kinase  domain  of  KIT.  We  herein  report  a  case  of  familial  systemic  mastocytosis  with
the  rare  KIT  K509I  germ  line  mutation  affecting  two  family  members:  mother  and  daughter.  In  vitro
treatment  with imatinib,  dasatinib  and PKC412  reduced  cell  viability  of  primary  mast  cells  harboring  KIT
K509I  mutation.  However,  imatinib  was  more  effective  in  inducing  apoptosis  of  neoplastic  mast  cells.eywords:
amilial mastocytosis
509I KIT mutation
yrosine kinase inhibitors
matinib
asatinib
Both  patients  with  familial  systemic  mastocytosis  had  remarkable  hematological  and  skin improvement
after  three  months  of imatinib  treatment,  suggesting  that it may  be  an  effective  front  line  therapy  for
patients  harboring  KIT  K509I  mutation.
©  2014  Elsevier  Ltd. All  rights  reserved.KC412
. Introduction
Mast cell diseases are myeloproliferative neoplasms character-
zed by an abnormal proliferation and accumulation of mast cells
MC) in different tissues [1]. Clinical presentation is heterogeneous,
anging from skin-limited disease (cutaneous mastocytosis) to
ore aggressive variants (systemic mastocytosis, SM)  that may  be
ssociated with multiorgan dysfunction/failure and shortened sur-
ival [2–8]. Although rare, cases of familial mastocytosis affecting
wo or more generations of the same family have been described,
ost of them are diagnosed with the cutaneous form of the dis-ase [9–13]. The presence of KIT mutations in familial mastocytosis
s variable and may  be associated with gastrointestinal stromal
umors (GISTs) [14–17].
∗ Corresponding author at: Hematology and Hemotherapy Center, University of
ampinas, Rua Carlos Chagas, 480, CEP 13083-878, Campinas, SP, Brazil.
el.: +55 19 3521 8734; fax: +55 19 3289 1089.
E-mail addresses: ftraina@fmrp.usp.br, fabiolatraina@gmail.com (F. Traina).
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145-2126/© 2014 Elsevier Ltd. All rights reserved.In a relatively high proportion of SM cases, the clonal nature of
the disease can be established on the basis of the demonstration of
gain-of-function mutations involving the tyrosine kinase domain
of KIT in lesional skin and BM cells [1]. The proto-oncogene KIT
encodes a tyrosine kinase receptor that is stimulated by its ligand,
the stem cell factor (SCF) [18]. Binding of SCF to KIT promotes
dimerization and autophosphorylation of the receptor at speciﬁc
tyrosine residues, leading to the activation of signal transduction
pathways, including the Ras-Raf-MAP (mitogen-activated protein)
kinase cascade, phosphatidylinositol-3-kinase (PI3K), Src family
kinases, and STATs [18–20]. The best characterized KIT mutation is
the Asp816Val (D816V) substitution, which results in ligand inde-
pendent autophosphorylation of the KIT receptor [20,21]. While the
tyrosine kinase inhibitor imatinib mesylate is effective in killing KIT
wild type mast cells, the same is not observed in KIT D816V cells
[22–24]. Genetic or epigenetic changes associated with KIT muta-
tions might be capable of altering susceptibility to certain drugs
[25,26]. We  herein report a case of familial SM with the rare KIT
K509I mutation and describe its in vitro sensitivity to the tyro-
sine kinase (TK) inhibitors imatinib, dasatinib and PKC412, and
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Fig. 1. Mast cell inﬁltration in bone marrow and spleen from patient 1. (A) Bone marrow smear showing inﬁltration by mast cells; (B) Bone marrow histology: intense
hypercellularity due to inﬁltration by large nests of mast cells. Scarce hematopoietic remnants of the erythroblastic and megakaryocytic series are seen (HE, 400×); (C)
Spleen  histology in detail, dense inﬁltration of the spleen by mast cells, and some foci of necrosis (HE, 250×). (D) The spleen is diffusely inﬁltrated by neoplastic mast cells,
i
F
h
h
nnterspersed with remnants of white pulp (HE, 100×).
ig. 2. Mast cell inﬁltration in bone marrow and spleen from patient 2. (A) Bone marro
ypercellularity due to inﬁltration by large nests of mast cells. Scarce hematopoietic rem
istology: inﬁltration of superﬁcial dermis by groups of mast cells in a perivascular patter
uclei, and abundant granular cytoplasm (HE, 1000×).w smear showing inﬁltration by mast cells; (B) bone marrow histology: intense
nants of the erythroblastic and megakaryocytic series are seen (HE, 400×); (C) skin
n (HE, 250×); (D) skin histology in detail, inﬁltrating neoplastic cells display round
P. de Melo Campos et al. / Leukemia R
Table  1
Clinical and laboratory features of mastocytosis patients.
Patient #1 Patient #2
Age in years, median (range) 33 17
Sex  (M/F) F F
Clinical characteristics, N (%)
Urticaria pigmentosa Yes Yes
Cutaneous symptomsa Yes Yes
Constitutional symptomsb No No
Mediator-related symptomsc No No
Weight lossd No No
Hepatomegalye Yes No
Splenomegalye Yes Yes
Lymphadenopathyf No No
Laboratory characteristics, median (range)
Hemoglobin, g/dL 11.1 13.0
White blood cell count, ×103/L 4.08 7.94
Eosinophil count, ×103/L 0.04 1.8
Monocytes count, ×103/L L 0.08 0.42
Platelet count, ×103/L 62.2 163.0
Albumin, g/dL (3.5–5.0) 2.6 3.71
Serum alkaline phosphatase, U/L (40–150) 77 90
AST, U/L (7–40) 17 21
Total bilirubin, mg/dL (0–1.5) 0.18 0.40
INR/aPTT (<1.13/22.1–33.7) 1.02/29.0 1.00/32.3
LDH, U/L (100–220) 297 241
Upper Gastrointestinal Endoscopy Normal Normal
Abbreviations: AST, aspartate aminotransferase; LDH, Lactate dehydrogenase; INR,
international normalized ratio; aPTT, activated partial thromboplastin time.
a Includes pruritus, ﬂushing, urticaria, and angioedema.
b Includes weight loss, fever, chills, and night sweats.
c Includes headache, dizziness/lightheadedness, syncope/presyncope, hypoten-
sion, anaphylaxis, palpitation/tachycardia, bronchoconstriction/wheezing, and
peptic ulcer disease.
d Weight loss of >10% of normal body weight over a period of 6 months or less.
e Palpable splenomegaly or hepatomegaly.
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(WHO) criteria for the diagnosis of systemic mastocytosis [6];Lymphadenopathy on palpation or imaging.
he good response of both patients to three months of imatinib
reatment.
. Materials and methods
.1. Patients
Two patients (case 1 [mother], and case 2 [daughter]), and the parents of
ase 1 were included in the study. Written informed consent was obtained
rom subjects and from the guardians on behalf of the minor enrolled in the
tudy. The Institutional Review Board approved this research and the consent
rocedure.
.2. Primary hematopoietic cells and tyrosine kinase inhibitors
Bone marrow samples from patients 1 and 2 before treatment were submitted to
icoll Hypaque density gradient. CD3+ cells were sorted using anti-CD3 monoclonal
ntibody and MACS® Magnetic Cell sorting technique (Miltenyi Biotec, Bergisch
ladbach, Germany). BM mononuclear cells were treated in vitro with imatinib
5  M),  dasatinib (80 nM)  and PKC412 (100 nM)  diluted in DMSO, or with DMSO only
control cells) for 4, 8 and 12 days. Imatinib mesylate and PKC412 were kindly pro-
ided by Novartis (Basel, Switzerland); dasatinib was obtained from Bristol-Myers
quibb (New Jersey, USA).
.3. KIT, SF3B1, TET2, DNMT3A and ASXL1 sequencing analysis
Genomic DNA was  obtained from total BM cells, CD3+ BM cells and oral mucosa
f  cases 1 and 2, and from PB of all individuals using the phenol: chloroform method.
irect sequencing was  performed on all coding exons of KIT (exons 1–21) and TET2
exons 3–11), and hotspot regions of DNMT3A (exons 18–23), ASXL1 (exon 12), and
F3B1 (exons 13–16). Primer sequences are described in Supplementary Table 1.
idirectional sequencing was performed by standard techniques using an ABI 3500
NA analyzer (Life Technologies, Carlsbad, USA).
Supplementary Table 1 related to this article can be found, in the online version,
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2.4. Assessment of cell growth by methythiazoletetrazolium (MTT) assay
A total of 5 × 104 BM mononuclear cells per well were plated in a 96-well plate
in  Alpha MEM  supplemented with 5 ng/mL IL-3 and 20 ng/mL SCF at different con-
centrations of imatinib (5 M),  dasatinib (80 nM), and PKC412 (100 nM)  or DMSO
for  4, 8 and 12 days. 10 L of a 5 mg/mL solution of MTT  was added to the wells and
incubated at 37 ◦C for 4 h. The reaction was  stopped by using 100 L of 0.01 N HCl
in  anhydrous isopropanol. Cell growth was evaluated by measuring absorbance at
570 nm.  All conditions were tested in six replicates.
2.5. Assessment of apoptosis by Annexin-V/PI staining
A total of 2.5 × 105 BM mononuclear cells per well were plated in a 12-well
plate in alpha MEM  supplemented with 5 ng/mL IL-3 and 20 ng/mL SCF at different
concentrations of imatinib (5 M),  dasatinib (80 nM), PKC412 (100 nM)  or DMSO
for  4, 8 and 12 days. Cells were washed twice with PBS and resuspended in binding
buffer containing 1 g/mL APC labeled Annexin-V. All specimens were analyzed on
a  FACSCalibur after incubation for 15 min  at room temperature in a light-protected
area. Ten thousand events were acquired for each sample. All conditions were tested
in triplicates.
2.6. Western blotting
Equal amounts of protein obtained from BM mononuclear cells of patients 1 and
2  treated with imatinib (5 M),  dasatinib (80 nM), PKC412 (100 nM)  or DMSO for 12
days were submitted to Western blot and immunobloting analysis with speciﬁc
antibodies against phospho-P70S6K and P70S6K (Santa Cruz Biotechnology; Santa
Cruz,  CA, USA) and ECLTM Western Blotting Analysis System (Amersham Pharmacia
Biotech; Buckinghamshire, England), as described [27].
2.7. Statistical analysis
Statistical analyses were performed using GraphPad Instat 5 (GraphPad Soft-
ware, Inc., San. Diego, CA, USA). For comparisons, a Student’s t-test was used. A
p-value < 05 was considered as statistically signiﬁcant.
3. Results
3.1. Patientsc´linicopathological features
Case 1 was  a 33 year-old woman  with a chronic history of
pruritic skin rash who  was referred to our outpatient service for
evaluation of massive splenomegaly (25 cm in length by palpation
below the left subcostal margin) and pancytopenia. She had neither
comorbidities nor any familial history of hematological malignan-
cies. The patient had no siblings and had only one daughter (case
2). Skin biopsy revealed extensive mast cells inﬁltration, and BM
biopsy section revealed 70% of mast cells. BM aspirate showed 51%
of mast cells, with less than 10% of atypical and spindle shaped ele-
ments (Fig. 1A and B). Bone marrow cytogenetics was normal (46,
XX). Tryptase level was 165.0 g/L (reference range: 1.0–11.0 g/L).
During follow up, the patient presented with spontaneous splenic
rupture, and spleen histology revealed dense inﬁltration of mast
cells (Fig. 1C and D). The patient had no coagulopathy and under-
went an emergency open splenectomy, with subsequent resolution
of cytopenias. Treatment with Cladribine was  started, but after two
cycles of chemotherapy, there was neither clinical response nor
reduction in bone marrow mast cells inﬁltration. Fourteen months
later, the patient was  started on imatinib treatment (400 mg  daily).
Her daughter (case 2), a 17 year-old woman, was also evaluated for
an insidious history of diffuse skin rash and pruritus. Skin biopsy
showed moderate mast cells inﬁltration, with 70% of mast cells in
BM biopsy section. Bone marrow aspirate revealed 17% of mast cells
with only 3% of atypical elements (Fig. 2A–D), and normal karyo-
type. Tryptase level was  130.0 g/L. She had no organomegaly and
her blood counts were normal. The patient was started on imatinib
treatment (400 mg  daily).
Both patients fulﬁlled the 2008 World Health Organizationthe major criterion (multifocal, dense inﬁltrates of MC in bone
marrow sections) plus one minor criterion (total tryptase persis-
tently exceeds 20 ng/mL). Patient 1 was diagnosed with aleukemic
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Fig. 3. KIT K509I germ line mutation. Chromatograms derived from Sanger sequencing analysis are illustrated. Black arrows indicate KIT K509I mutation (c. 1526 A > T) found
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An  patient 1 (A) and patient 2 (B). The mutation was found in DNA samples obtained
s  indicated. (C and D) Sanger sequencing analysis from peripheral blood of the mo
ast cell leukemia: she had massive splenomegaly with hyper-
plenism, pancytopenia, signiﬁcant BM inﬁltration by MC  with
ecreased normal hematopoiesis and no mast cells in the periph-
ral blood. Patient 2 was diagnosed with indolent systemic
astocytosis (no “C” ﬁndings, only one “B” ﬁnding [30% inﬁl-
ration by MC  in BM biopsy], and no evidence of associated
on-MC lineage clonal hematological malignancy). Patients 1 and
 suffered from the morphologic subvariant called well differen-
iated SM (WDSM), characterized by mature phenotype with a
ound shape, fully granulated cytoplasm, and a centrally located
ound nucleus [3,28,29]. Patientsc´linical characteristics are shown
Table 1).
.2. Identiﬁcation of KIT K509I mutation
Sequencing analysis revealed an A > T substitution at position
547 in exon 9 of KIT, resulting in a change from lysine to isoleucine
t amino acid 509 (c.1547 A > T, p.K509I). The mutation was found
n DNA samples obtained from oral mucosa, CD3+ and total cells
rom peripheral blood and total bone marrow cells from cases 1
nd 2 (Fig. 3A and B). No other mutations in KIT,  including KIT
816V, were found. Patients were wild type for TET2, DNMT3A,
SXL1, and SF3B1.  The parents of case 1 were wild type for KIT, asells derived from total bone marrow (BM), peripheral blood CD3 and oral mucosa,
nd the father of case 1, respectively, revealed wild-type KIT.
detected by sequencing analysis (Fig. 3C and D). These results indi-
cate that the KIT K509I was  a germ line mutation acquired de novo
by patient 1, which was subsequently transmitted to her daughter
(patient 2).
3.3. Sensitivity of KIT K509I bone marrow cells to tyrosine kinase
inhibitors
In vitro treatment of primary bone marrow mononuclear cells
harboring the KIT K509I mutation from patients 1 and 2 resulted in
variable effects according to the drug used and treatment duration,
as evaluated by MTT  and Annexin-V/PI assays. Imatinib treatment
resulted in signiﬁcant reduction in cell growth (days 4, 8 and 12
of culture) and an increase in apoptosis (days 8 and 12) in both
patients (all p ≤ .03). Dasatinib resulted in a statistically signiﬁcant
decrease in cell growth in both patients at days 8 and 12 (all p ≤ .05),
and there was also a higher apoptosis ratio at day 12 of culture in
patient 1 (p = .03). PKC412 signiﬁcantly decreased cell growth at day
8 in patient 1 (days 4 and 8) and in patient 2 (day 4) (all p ≤ .03),
but no effect in apoptosis ratio was seen (Fig. 4A–B).
To further evaluate the effect of tyrosine kinase inhibitors
treatment on PI3K/Akt/P70S6K signaling pathway, that is charac-
teristically stimulated by SCF/KIT, total protein extract obtained
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Fig. 4. Imatinib, dasatinib and PKC412 modulate in vitro cell growth and apoptosis of KIT K509I cells. (A) Cell growth: mononuclear bone marrow (BM) cells from patients
1  and 2 were subjected to treatment with imatinib (5 M),  dasatinib (80 nM), and PKC412 (100 nM) or with DMSO alone (control). Cell growth was determined at days 4, 8,
and  12 of treatment, and values were normalized by untreated cells. Results are shown as mean ± SD of six replicates. *p < .05; **p  < .01; compared to control cells at the same
day  of culture; Student’s t test; (B) apoptosis: mononuclear BM cells from patients 1 and 2 were treated with imatinib (5 M), dasatinib (80 nM), and PKC412 (100 nM)  or
with  DMSO alone (control). Apoptosis was determined by Annexin/PI assay after 4, 8, and 12 days of treatment. Results are shown as mean ± SD of three replicates. *p < .05;
**p  < .01; compared to control cells at the same day of culture; Student’s t test; (C) protein extracts obtained from mononuclear BM cells of patients 1 and 2 treated with
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ntibodies against phospho-P70S6K and P70S6K, as indicated. The reduction in P7
otable.
rom the KIT K509I cells treated or not with imatinib, dasatinib
nd PKC412 for 12 days were tested for total and phosphorylated
70S6K. A reduced protein phosphorylation was  observed for all
rugs in both patients (Fig. 4C).
.4. Clinical response to imatinib mesylate
Patients were started on imatinib treatment (400 mg  daily),
nd after three months of treatment, both patients had a marked
eduction of skin rash and mast cells percentage in bone marrow
spirate; 1.5% and 0.5% of mast cells, with no atypical elements,
n BM aspirates for cases 1 and 2, respectively. Photographs of
he skin from patient 1 before and after imatinib treatment are
hown (Fig. 5A–D). Also, tryptase levels normalized after imatinib
reatment: 1.28 g/L and 1.15 g/L in patients 1 and 2, respec-
ively. According to 2003 treatment response proposed criteria
or aggressive systemic mastocytosis [5], patient 1 had major
esponse/complete remission. Patients remain stable following one
ear of treatment.for 12 days were used for Western blot and immunobloting analysis with speciﬁc
phosphorylation protein level after imatinib, dasatinib, and PKC412 treatments is
4. Discussion
We herein provide a report of KIT K509I germ line mutation
in familial systemic mastocytosis. The mutation was acquired de
novo by patient 1 and was  subsequently transmitted to her only
daughter (patient 2). Zhang and colleagues [30] have ﬁrst described
this mutation in a family with systemic mastocytosis, in which the
K509I mutation was  present exclusively in the affected individuals.
Also, they obtained a negative screening for KIT K509I in 217 con-
trol individuals, showing that it is a mutation than a previously
undescribed polymorphism. Recently, Chan et al. characterized
KIT K509I mast cells as showing a well-differentiated pheno-
type, with enhanced proliferation, granulation, and activation
[31].
Tyrosine kinase inhibitors are treatment choices for mastocy-
tosis, but clinical response is variable and is associated with the
speciﬁc KIT mutation found and with the conformational changes
that it provokes, affecting or not drug binding site. Zermati et al. [23]
have shown that imatinib can inhibit KIT wild type kinase activity,
but not KIT D816V mutation [32]. Dasatinib has in vitro activity
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aig. 5. Clinical response to imatinib mesylate. (A and B) Diffuse skin rash, with inﬁ
kin  rash after three months of imatinib mesylate treatment. The scar of prior splen
gainst KIT D816V mutation, but no signiﬁcant clinical response
as found in patients harboring this mutation [23,32–34]. The
ulti-targeted TK inhibitor PKC412 has growth-inhibitory effects
n cells exhibiting KIT D816V mutation [35], but clinical responses
ere variable and it is not clear which subgroups of mastocytosis
atients could beneﬁt from the treatment [8].
Due to the heterogeneity in drug response in mastocytosis
atients, we aimed to test the sensitivity of the KIT K509I mast
ells to the three different TK inhibitors. Our study provides evi-
ence of P70S6K inhibition in primary cells harboring KIT K509I
utation after imatinib, dasatinib and PKC412 treatments. P70S6K
s a protein involved in cell proliferation that is activated after
CF/KIT stimulation of the PI3K/Akt/P70S6K pathway [36], sug-
esting that the TK inhibitors tested may  be capable of reducing
ell proliferation. In our in vitro studies, imatinib, dasatinib and
KC412 were able to induce apoptosis and reduce cell viability of
ells harboring KIT K509I mutation, but imatinib was more effective
n inducing apoptosis in vitro. This difference could be secondary
o conformational changes induced by KIT K509I mutation that
ay  alter drug binding sites, as described for other KIT mutations
23,33,37,38]. The effect of TKI therapy could be better evaluated
n sorted mast cells. However, due to sample and technical lim-
tations, we could not perform functional studies on sorted mast
ells. Patientsr´emarkable clinical and laboratory response to imat-
nib corroborate our in vitro results. Recent studies have described
hat additional genetic lesions can be present in patients with mas-
ocytosis [25,26]. Genetic or epigenetic changes associated with
IT mutations might be capable of altering susceptibility to cer-
ain drugs. However, we did not observe hotspot mutations in
ET2, DNMT3A, ASXL1 and SF3B1.  Imatinib has induced good clin-
cal responses in both patients studied, reducing tryptase levels,
one marrow and skin mast cell inﬁltration. A satisfactory clinical
esponse to imatinib was also shown in the work by Zhang et al.
30], suggesting that this drug may  be a good ﬁrst choice for the
reatment of patients harboring KIT K509I mutation.The identiﬁcation of speciﬁc KIT mutations in patients with
amilial mastocytosis and the study of mutations’ sensitivity to TK
nhibitors may  contribute to the better understanding of the mech-
nism of disease and in deﬁning treatment choices. Although rare,e appearance, observed in patient 1 before imatinib therapy; (C and D)  improved
y can also be seen.
the screening for KIT K509I mutation should be considered in all
cases of familial mastocytosis.
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